• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.140 -0.020 (-0.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
November 10, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
November 03, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
October 09, 2025
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models 
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
October 06, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
September 02, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
August 28, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Participate in Upcoming Investor Conferences
August 27, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
August 12, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
June 12, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
May 14, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
May 14, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
May 13, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces First Quarter 2025 Results and Business Updates
May 12, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
May 12, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
May 05, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
April 28, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces Chief Financial Officer Transition
March 20, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
March 05, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
February 24, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
January 13, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
December 12, 2024
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
December 09, 2024
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Participate in Upcoming Investor Conferences
November 06, 2024
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
November 04, 2024
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
October 22, 2024
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
October 21, 2024
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
October 18, 2024
Webinar to be held on Tuesday, October 22, at 8:00 a.m. ET 
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
October 03, 2024
Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities 
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Participate in Upcoming Investor Conferences
August 28, 2024
From Editas Medicine, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap